Table 1.
Baseline demographics and clinical characteristics of the ORION-8 study participants
| Characteristic | ORION-8 population, N = 3 274 |
|---|---|
| Age (years), mean ± SD | 64.9 ± 9.9 |
| Age ≥ 65 years, n (%) | 1849 (56.5) |
| Sex, male, n (%) | 2216 (67.7) |
| Race, n (%) | |
| White | 3041 (92.9) |
| Black/African American | 188 (5.7) |
| Asian | 27 (0.8) |
| Other (not answered) | 18 (0.5) |
| Ethnicity, Hispanic/Latino, n (%) | 199 (6.1) |
| ASCVD status, n (%) | |
| ASCVD | 2709 (82.7) |
| ASCVD risk equivalent | 565 (17.3) |
| LDL-C (mmol/L), mean ± SD | |
| Overall population | 2.9 ± 1.2 |
| ASCVD | 2.7 ± 1.0 |
| ASCVD risk equivalent | 3.8 ± 1.4 |
| ≥ 1 LMT at baseline, n (%) | 3052 (93.2) |
| Any statin, n (%) | 2902 (88.6) |
| High-intensity statin, n (%) | 2244 (68.5) |
| Ezetimibe, n (%) | 544 (16.6) |
| Diabetes, n (%) | 1104 (33.7) |
| Weight (kg), mean ± SD | 88.2 ± 19.13 |
| BMI (kg/m2), mean ± SD | 30.24 ± 5.76 |
| Smoking status, n (%) | |
| Current smoker | 494 (15.1) |
| Ex-smoker | 1480 (45.2) |
| Never smoked | 1291 (39.4) |
Baseline refers to ORION-8 baseline, except for medical history and LDL-C from the parent trials.
ASCVD, atherosclerotic cardiovascular disease; BMI, body mass index; LDL-C, low-density lipoprotein cholesterol; LMT, lipid-modifying therapy; N, total number of patients; n, number of patients in each category; SD, standard deviation.